Viyash Scientific Limited · NSE:VIYASH
Viyash Scientific — SeQuent Scientific — Q4 FY2019 Earnings Presentation
20 slides from Viyash Scientific's earnings presentation, May 14, 2019
Slide 1: Earnings Presentation Q4 & FY19
Earnings Presentation Q4 & FY19 MAY 14, 2019
Slide 2: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "pl
Slide 3: Q4 & FY19 Performance Review
>) Sequent fae Proven Ability In Life Sciences Lo) ALIVIRA Q4 & FY19 Performance Review More than SeQuent Scientific Limited Pharma www.sequent.in
Slide 4: Momentous Year
Momentous Year “ This has been a year of strong performance wherein our Revenue and EBITDA grew by 22% and 52% respectively, with a 250 bps margin improvement and a 5.6x growth in PAT. The all-round growth was fueled by execution excellence across both APIs and formulations. We have significantly sc
Slide 5: Results at a glance
Results at a glance All values in ₹ Mn Revenues YoY Revenues YoY 22% 21% FY19 10,393 4Q19 2,819 FY18 8,495 4Q18 2,328 EBITDA YoY EBITDA YoY Q4 FY2019 FY2019 FY19 1,327 52% 4Q19 402 31% FY18 871 4Q18 308 PAT YoY PAT YoY FY19 570 5.6x 4Q19 214 2.5x FY18 102 4Q18 84 Board recommends a dividend of ₹0.2
Slide 6: Strong performance across businesses
Strong performance across businesses YoY% Key Highlights Revenue Distribution FY19 FY18 YoY% (Constant currency) Formulations 7,145 6,307 13.3% 13.8% For FY19: Overall business growth of 22.4% Europe 3,664 3,168 15.7% 7.8% ▪ API business grew 48.5% on the back of increasing Turkey 962 1,160 (17.1%)
Slide 7: FY19 Business Review
Sequent ay Proven Ability In Life Sciences wae FY19 Business Review More than SeQuent Scientific Limited www.sequent.in Pharma
Slide 8: Formulations
Formulations 35+ 80+ 35+ 50%+ Leading revenue Products Under Countries with Launches Sales to regulated driver Development marketing presence markets Revenues in ₹ Mn Key Highlights YoY% FY19 FY18 Robust growth across geographies, driven by 35+ launches and improved market share (cc) across key geog
Slide 9: Turkey & Europe
Turkey & Europe Key Highlights - Turkey Key Highlights - Europe Turkey had implemented two key initiatives – E-Prescription and Supply chain challenges continue in Europe; region grew 7.8% Veterinary Pharmaceutical Product Tracking. Q4 saw normalcy during the year, over 2x industry growth rate in sa
Slide 10: APIs
APIs 26 3 1.9x 50%+ Scaling the Commercial APIs Manufacturing Asset turn Incremental growth capability curve facilities from global top 10 vs FY16 Revenues in ₹ Mn YoY% Key Highlights FY19 FY18 (cc) Margin expansion through focus on regulated markets and high value products 3,248 2,188 38.3% Deepeni
Slide 11: Growth driven by top-5 customers
Growth driven by top-5 customers Customer Customer A Growth FY19 vs. FY18 2.0x % Contribution of sales 11% 2.4x Growth with top-5 customers Customer B 2.3x 8% Customer C 2.7x 7% Customer D Customer E 5.0x 1.9x 5% 5% 54% Contribution of top 10 customers to API sales 11
Slide 12: Scaling value curve
Scaling value curve US filed / EU-CEP Pipeline approved approvals API 5 US and 3 CEP filings during the year 14 17 10 Expanded R&D team in India, adept to execute Pipe Line of 35+ products 10+ projects per annum 20+ new filings in US in next 3 years with a market size of US$ 500Mn+ Developed capabil
Slide 13: Consistent delivery
Sequent Proven Ability In Life Sciences More than Pharma Consistent delivery ALIVIRA SeQuent Scientific Limited www.sequent.in
Slide 14: Delivering consistent outcome
Delivering consistent outcome All values in ₹ Mn Revenue Revenue 2,819 2,517 2,705 2,352 2,090 2,249 2,328 1,943 1,975 2,003 1,700 1,097 10,393 8,495 6,890 Q1 Q2 Q3 Q4 FY17 FY18 FY19 EBITDA EBITDA 12.7% 13.1% 12.8% 14.3% 10.6% 10.0% 13.2% 9.6% 9.5% 10.3% 1327 11.2% 7.6% 8.4% 6.2% 5.2% 355 402 250 32
Slide 15: Consolidated Financials
Consolidated Financials All values in ₹ Mn Q4’19 Q4'19 Q3'19 Q4’18 FY19 FY19 FY18 PARTICULARS Audited Audited Unaudited Unaudited Audited Audited Audited Revenue from Operations 2,819 2,827 2,705 2,328 10,393 10,401 8,494 Material Consumption (1,442) (1,467) (1,413) (1,235) (5,430) (5,455) (4,625) G
Slide 16: Key Balance Sheet items
Key Balance Sheet items All values in ₹ Mn ROCE Net debt to EBITDA Particulars Mar-19 Mar-18 3.75 15.1% 11.8% 2.81 Shareholders' funds 7,067 6,476 7.8% 1.84 1.52 2.9% Minority Interest 403 370 FY17 FY18 FY19 FY19 Q4* FY17 FY18 FY19 FY19 Q4* Net Borrowings 2,452 2,451 *Quarter Annualised Highlights I
Slide 17: FY19 snapshot & FY20 Outlook
>) Sequent fae Proven Ability In Life Sciences Lo) ALIVIRA FY19 snapshot & FY20 Outlook More than SeQuent Scientific Limited Pharma www.sequent.in
Slide 18: Creating value for all stake-holders
Creating value for all stake-holders Delivered on Expectations in FY19 FY20 Outlook FY20 Outlook Maintain Top line growth What we planned? What we delivered? momentum ▪ High-teen ▪ Revenue up 22% Margin expansion of revenue growth 200bps ▪ EBITDA expansion ▪ 200+ bps margin 250 bps YoY expansion 18
Slide 19: Thank You
Sequent Proven Ability In Life Sciences ALIVIRA Thank You SeQuent Scientific Limited CIN: L99999MH1985PLC036685 Registered Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22,Wagle Industrial Estate, Thane (W) - 400 604, Maharashtra Tel No: +91 22 4111 4777 | Website: www.sequent.in | E
Slide 20: For details, feel free to contact
For details, feel free to contact: Tushar Mistry Diwakar Pingle Abhishek Singhal Chief Financial Officer Christensen Investor Relations Investor Relations Consultant +91 22 4111 4717 +91 22 4215 0210 [email protected] [email protected] [email protected] Registered Office: 301/A, ‘Dosti